Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio’s New Botulinum Toxin Development Project

Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio’s New Botulinum Toxin Development Project

SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) — Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to participate in WizMedi Bio’s new botulinum toxin development project. Their involvement is expected to provide a profound boost to the product development and registration processes.

The long-term collaboration between Dr. Johnson and Professor Dressler has shaped the global botulinum toxin landscape over the past decades. Dr. Johnson, a retired professor of bacteriology at the University of Wisconsin-Madison in the US, has devoted more than four decades to botulinum toxin research, authored more than 200 publications and founded three botulinum toxin companies. His prominent contributions led to the development of the first botulinum toxin drug.

Professor Dressler, Head of the Department of Movement Disorders at Hannover Medical School in Germany, has been at the forefront of both translational botulinum toxin research and the development of all major clinical applications including dystonia, spasticity, migraine, hyperhidrosis and aesthetic indications. Having introduced most of the major botulinum toxin drugs to international markets, he is a sought-after advisor to the botulinum toxin industry.

WizMedi Bio recently announced the acquisition of exclusive rights to the newly developed and patented botulinum toxin type A6 strain from the Wisconsin Alumni Research Foundation (WARF), an affiliate of the University of Wisconsin.

Related link:

During their visit to Korea, Dr. Johnson and Professor Dressler BNC Korea’s advanced manufacturing and research facilities, confirming the positive outlook for the project’s success. BNC Korea and WizMedi Bio formed a strategic partnership in 2023 to research and develop new botulinum toxin products.

Dr. Johnson expressed his enthusiasm, saying, “I am excited about the novelty of A6 botulinum toxin and its potential as a new drug in the growing botulinum field. My visit to WizMedi Bio and their professionalism has only strengthened my confidence in this project.”

Dr. Yonghun Choi, CEO of WizMedi Bio, said: “The two experts are already mythical figures in the field of botulinum toxin, and it is an absolute pleasure for us to work with both of them at the same time. We look forward to working with them work together to bring our new potent A6 toxin to market as quickly as possible.”

Social ties


Media contact

Company: Wizmedi Co., Ltd.

Contact person: Media team





: Wizmedi Co., Ltd.